Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.

Trial Details

NCT ID
NCT05205200
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • SHR-1316
  • SHR6390
  • Nab paclitaxel
  • SERD
  • AI
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Females ≥18 years and ≤ 75 years old;
  • Histologically confirmed HR + / HER2- invasive breast cancer (specific definition: immunohistochemical detection of ER\> 10% tumor cell positive is…
  • Subtype of similarity network fusion-2 (SNF-2) confirmed by the Department of Pathology and Key Laboratory of Breast Cancer of Fudan University Aff…
  • Locally advanced breast cancer (incapable of radical local treatment) or recurrent metastatic breast cancer;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →